Terms: = Germ cell tumor AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
2250 results:
1. In Silico Transcriptomic Expression of MSR1 in Solid tumors Is Associated with Responses to Anti-PD1 and Anti-ctla4 Therapies.
Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
[TBL] [Abstract] [Full Text] [Related]
2. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract] [Full Text] [Related]
3. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract] [Full Text] [Related]
4. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?
Reschke R; Deitert B; Enk AH; Hassel JC
Front Immunol; 2024; 15():1385781. PubMed ID: 38562921
[TBL] [Abstract] [Full Text] [Related]
5. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
6. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract] [Full Text] [Related]
7. tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Wnt signaling for improved glioma immunotherapy.
Gutova M; Hibbard JC; Ma E; Natri HM; Adhikarla V; Chimge NO; Qiu R; Nguyen C; Melendez E; Aguilar B; Starr R; Yin H; Rockne RC; Ono M; Banovich NE; Yuan YC; Brown CE; Kahn M
Front Immunol; 2024; 15():1342625. PubMed ID: 38449858
[TBL] [Abstract] [Full Text] [Related]
9. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
10. Identification and validation of a glycolysis-related taxonomy for improving outcomes in glioma.
Ying T; Lai Y; Lu S; E S
CNS Neurosci Ther; 2024 Feb; 30(2):e14601. PubMed ID: 38332637
[TBL] [Abstract] [Full Text] [Related]
11. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
13. Incidence of melanoma and non-melanoma skin cancer in patients with celiac disease: a systematic review and meta-analysis.
Kim PJ; Lansang RP; Ko E; Abu-Hilal M
Eur J Dermatol; 2023 Oct; 33(5):506-513. PubMed ID: 38297926
[TBL] [Abstract] [Full Text] [Related]
14. Recurrent Cushing's Disease Caused by a TPIT-Lineage Densely Granulated Corticotroph Pituitary Neuroendocrine tumor: A Case Report.
Wu W; Fu X; Guo W; Chen H
Neuro Endocrinol Lett; 2024 Jan; 45(1):76-80. PubMed ID: 38295430
[TBL] [Abstract] [Full Text] [Related]
15. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract] [Full Text] [Related]
16. Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.
Pan H; Liu P; Kroemer G; Kepp O
Int Rev Cell Mol Biol; 2024; 382():279-294. PubMed ID: 38225106
[TBL] [Abstract] [Full Text] [Related]
17. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis.
Pietrzykowski MO; Vranceanu AM; Macklin EA; Mace RA
Qual Life Res; 2024 May; 33(5):1233-1240. PubMed ID: 38214851
[TBL] [Abstract] [Full Text] [Related]
18. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract] [Full Text] [Related]
19. Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
Benhima N; Belbaraka R; Langouo Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):69-73. PubMed ID: 38193381
[TBL] [Abstract] [Full Text] [Related]
20. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
[Next]